Valganciclovir for Symptomatic Congenital Cytomegalovirus Disease
Author(s) -
David W. Kimberlin,
Penelope Jester,
Pablo J. Sánchez,
Amina Ahmed,
Ravit AravBoger,
Marian G. Michaels,
Negar Ashouri,
Janet A. Englund,
Benjamin Estrada,
Richard F. Jacobs,
José R. Romero,
Sunil K. Sood,
M. Suzanne Whitworth,
Mark J. Abzug,
Mary T. Caserta,
Sandra Fowler,
Jorge LujánZilbermann,
Gregory A. Storch,
Roberta L. DeBiasi,
Jin-Young Han,
A. Smythe Palmer,
Leonard B. Weiner,
Joseph A. Bocchini,
Penelope H. Dennehy,
Adam Finn,
Paul Griffiths,
Suzanne Luck,
Kathleen Gutierrez,
Natasha Halasa,
James Homans,
Andi L. Shane,
Mike Sharland,
Kari Simonsen,
John A. Vanchiere,
Charles R. Woods,
Diane L. Sabo,
Inmaculada Aban,
HuiChien Kuo,
Scott H. James,
Mark N. Prichard,
Jill Griffin,
Dusty Giles,
Edward P. Acosta,
Richard J. Whitley
Publication year - 2015
Publication title -
new england journal of medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 19.889
H-Index - 1030
eISSN - 1533-4406
pISSN - 0028-4793
DOI - 10.1056/nejmoa1404599
Subject(s) - valganciclovir , medicine , ganciclovir , cytomegalovirus , pediatrics , disease , cytomegalovirus infections , surgery , human cytomegalovirus , herpesviridae , virology , viral disease , virus
The treatment of symptomatic congenital cytomegalovirus (CMV) disease with intravenous ganciclovir for 6 weeks has been shown to improve audiologic outcomes at 6 months, but the benefits wane over time.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom